Vertex Pharma (VRTX) Tops Q2 EPS by 83c
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $525.00 -0.14%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.11, $0.83 better than the analyst estimate of $2.28. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.72 billion.
GUIDANCE:
Vertex Pharma sees FY2021 revenue of $7.2-7.4 billion, versus the consensus of $6.99 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
